Publication:
Virological Failure in HIV to Triple Therapy With Dolutegravir-Based Firstline Treatment: Rare but Possible.

dc.contributor.authorPena, M J
dc.contributor.authorChueca, N
dc.contributor.authorD'Avolio, A
dc.contributor.authorZarzalejos, J M
dc.contributor.authorGarcia, F
dc.date.accessioned2023-01-25T10:28:00Z
dc.date.available2023-01-25T10:28:00Z
dc.date.issued2018-12-10
dc.description.abstractWe describe a case of virological failure during initial treatment with tenofovir disoproxil fumarate/emtricitabine/dolutegravir twice daily, with concomitant rifampin treatment of staphylococcal infection, selection of R263K + E157Q, and low plasma dolutegravir levels. Using rifampin together with dolutegravir may require closer follow-up, and, if possible, plasma dolutegravir levels should be monitored.
dc.identifier.doi10.1093/ofid/ofy332
dc.identifier.issn2328-8957
dc.identifier.pmcPMC6324549
dc.identifier.pmid30631792
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324549/pdf
dc.identifier.unpaywallURLhttps://academic.oup.com/ofid/article-pdf/6/1/ofy332/33575984/ofy332.pdf
dc.identifier.urihttp://hdl.handle.net/10668/13411
dc.issue.number1
dc.journal.titleOpen forum infectious diseases
dc.journal.titleabbreviationOpen Forum Infect Dis
dc.language.isoen
dc.organizationHospital Universitario San Cecilio
dc.organizationHospital Universitario San Cecilio
dc.page.numberofy332
dc.pubmedtypeJournal Article
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectdolutegravir
dc.subjectfailure
dc.subjectfirstline
dc.titleVirological Failure in HIV to Triple Therapy With Dolutegravir-Based Firstline Treatment: Rare but Possible.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number6
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC6324549.pdf
Size:
176.2 KB
Format:
Adobe Portable Document Format